If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
=== Middle East === Israel: BCG was given to all newborns between 1955 and 1982. Iran: Iran's vaccination policy was implemented in 1984. Vaccination with the Bacillus Calmette–Guerin (BCG) is among the most important tuberculosis control strategies in Iran [2]. According to Iranian neonatal vaccination policy, BCG has been given as a single dose to children aged <6 years, shortly after birth or at first contact with the health services.
=== Warnings about dietary supplements === Between 2018 and 2023, the U.S. FDA issued 29 warning letters to American manufacturers of dietary supplements for making false claims of anti-disease effects from using products containing curcumin. In each letter, the FDA stated that the supplement product was not an approved new drug because the "product is not generally recognized as safe and effective" for the advertised uses, that "new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA", and that the "FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective".
==== Blue ==== Prussian blue, or blue, a coloring used in the treatment of radiation, cesium, and thallium poisoning, can turn the feces blue. Substantial consumption of products containing blue food dye, such as blue curaçao or grape soda, can have the same effect.
== Synthesis == Clicked peptide polymers are prepared by the azide-alkyne Huisgen cycloaddition also called the click reaction; which is commonly used in bioconjugation reactions to link molecules together with a stable triazole bridge. Peptide based polymers are produced from a cycloaddition variant of step-growth polymerization. The monomers used in this polymerization are oligopeptides with terminal azide and terminal alkyne groups
=== Residual stress === In physiological state soft tissues usually present residual stress that may be released when the tissue is excised. Physiologists and histologists must be aware of this fact to avoid mistakes when analyzing excised tissues. This retraction usually causes a visual artifact.
Sources: en.wikipedia.org
In general, GBS is a harmless commensal bacterium being part of the human microbiota colonizing the gastrointestinal and genitourinary tract of up to 30% of healthy human adults (asymptomatic carriers). Nevertheless, GBS can cause severe invasive infections, especially in newborns, the elderly, and people with compromised immune systems. S. agalactiae is also a common veterinary pathogen because it can cause bovine mastitis (inflammation of the udder) in dairy cows. The species name agalactiae meaning "of no milk", alludes to this.
$29 billion for shipbuilding; $25 billion for a proposed "Golden Dome" missile defense system; $25 billion for munitions; $25 billion for various infrastructure and housing improvements. $25 billion for the U.S. Coast Guard; $16 billion for military innovation and artificial intelligence, including money for kamikaze drones, uncrewed aircraft systems, drone boats, and underwater drones; $15 billion for nuclear deterrence; and $12 billion for improving military operations in the Indo-Pacific.
The Israeli Defense Force (IDF) actively recruits influencers on TikTok and other social media platforms, often with what commentators have dubbed "Thirst traps". In a separate case in 2021, the IDF awarded a TikToker who was one of its military police officers for promoting the image of Israel. She had more followers than IDF spokesperson Ran Kochav or Prime Minister Benjamin Netanyahu. Since 2021, TikTok has created "election centres" on its platform leading up to European Parliament elections. About 30% of EP lawmakers use TikTok to get their messages across and to dispel misinformation. In February 2024, the re-election campaign for then-US president Joe Biden announced that it had opened a TikTok account while taking "advanced safety precautions". Biden posted his first video during Super Bowl LVIII. The move was criticized by a number of lawmakers over security concerns. Since 2022, the Biden administration had briefed TikTokers on news items such as the Russo-Ukrainian war and student debt relief in the United States.
=== Academic service === Ben-Tal has served on the editorial boards of scientific journals including eLife, Journal of Biological Chemistry, and BBA Biomembranes. At present he is Senior Editor with Protein Science (since 2021), and Associate Editor with PLoS Computational Biology (since 2013). He has also participated in scientific committees associated with international computational biology conferences, including the Intelligent Systems for Molecular Biology (ISMB) and the European Conference on Computational Biology (ECCB). He is a member of the Edmond J. Safra Center for Bioinformatics at Tel Aviv University, where his laboratory is part of the center's research community.
The South African Defence Force (SADF) (Afrikaans: Suid-Afrikaanse Weermag) comprised the armed forces of South Africa from 1957 until 1994. Shortly before the state reconstituted itself as a republic in 1961, the former Union Defence Force was officially succeeded by the SADF, which was established by the Defence Act (No. 44) of 1957. The SADF, in turn, was superseded by the South African National Defence Force in 1994.
Sources: en.wikipedia.org
Gutierrez-Marcos JF, Roberts MA, Campbell EI, Wray JL (1996). "Three members of a novel small gene-family from Arabidopsis thaliana able to complement functionally an Escherichia coli mutant defective in PAPS reductase activity encode proteins with a thioredoxin-like domain and "APS reductase" activity". Proc. Natl. Acad. Sci. U.S.A. 93 (23): 13377–82. Bibcode:1996PNAS...9313377G. doi:10.1073/pnas.93.23.13377. PMC 24101. PMID 8917599. Setya A, Murillo M, Leustek T (1996). "Sulfate reduction in higher plants: Molecular evidence for a novel 5′-adenylylsulfate reductase". Proc. Natl. Acad. Sci. U.S.A. 93 (23): 13383–8. Bibcode:1996PNAS...9313383S. doi:10.1073/pnas.93.23.13383. PMC 24102. PMID 8917600. Bick JA, Aslund F, Chen Y, Leustek T (1998). "Glutaredoxin function for the carboxyl-terminal domain of the plant-type 5′-adenylylsulfate reductase". Proc. Natl. Acad. Sci. U.S.A. 95 (14): 8404–9. Bibcode:1998PNAS...95.8404B. doi:10.1073/pnas.95.14.8404. PMC 20988. PMID 9653199.
Later in January, NPR reported that "drug-seizure data suggest that the attacks are doing little to stop the flow of illegal narcotics into the United States." On March 6, 2026, the operation expanded to Ecuador when U.S. forces bombed Comandos de la Frontera as part of the Ecuadorian conflict (2024–present). The campaign was formally named on 13 November 2025 by Pete Hegseth, US secretary of defense, as an expansion of an operation bearing the same name announced by the United States Navy on 28 January 2025. It uses a hybrid fleet of vessels with robotics and autonomous systems to detect and combat alleged drug trafficking networks in the Western Hemisphere. According to an assessment by the Drug Enforcement Administration (DEA), the military strikes against suspected drug-trafficking vessels did not reduce the volume of cocaine entering the United States. Instead, the operations forced criminal organizations to change their smuggling techniques and at the same time eroded traditional law enforcement investigative techniques.
=== Further processing === The N-terminal fMet is removed from majority of proteins, both host and recombinant, by a sequence of two enzymatic reactions. First, peptide deformylase (PDF) deformylates it, converting the residue back to a normal methionine. Then methionine aminopeptidase (MetAP) removes the residue from the chain. MetAP only acts on proteins with second-position residues that are less bulky than valine. The N-terminal fMet, if not removed by PDF, seems to act as a degron, a signal for protein degradation.
== Treatment == The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks. Other treatment options are largely supportive, and do not alter the course of the disorder (with the possible exception of ruxolitinib, as discussed below). These options may include regular folic acid, allopurinol or blood transfusions. Dexamethasone, alpha-interferon and hydroxyurea (also known as hydroxycarbamide) may play a role. Lenalidomide and thalidomide may be used in its treatment, though peripheral neuropathy is a common troublesome side-effect. Splenectomy is sometimes considered as a treatment option for patients with myelofibrosis in whom massive splenomegaly is contributing to anaemia because of hypersplenism, particularly if they have a heavy requirement for blood transfusions. However, splenectomy in the presence of massive splenomegaly is a high-risk procedure, with a mortality risk as high as 3% in some studies. In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of myelofibrosis, and was associated with much improved overall survival rates compared to placebo. However, the beneficial effect of ruxolitinib on survival has been recently questioned.
SHG being a coherent process (spatially and temporally), it keeps information on the direction of the excitation and is not emitted isotropically. It is mainly emitted in forward direction (same as excitation), but can also be emitted in backward direction depending on the phase-matching condition. Indeed, the coherence length beyond which the conversion of the signal decreases is:
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.